Sanjay Chanda

Dr. Sanjay Chanda has over twenty years of experience in drug development, including product development, regulatory affairs, and product registration. Currently, Dr. Chanda serves as Chief Development Officer at Tioma Therapeutics. He is also a co-founder of Auration, Inc., an early stage pharmaceutical company focused on treating chronic hearing loss in humans. Previously, Dr. Chanda served as Senior Vice President, Drug Development at Anacor Pharmaceuticals until its acquisition by Pfizer in June of 2016. At Anacor, he was responsible for all aspects of CMC and Preclinical Safety and played key leadership roles in the development and approvals of KERYDIN® for the treatment of onychomycosis and EUCRISA® for the treatment of eczema. Previously, Dr. Chanda was Senior Director, Toxicology, Drug Metabolism and Pharmacokinetics at NeurogesX, Inc., prior to its acquisition by Acorda Therapeutics, where he played a leadership role in development of QUTENZA® for the management of neuropathic pain associated with postherpetic neuralgia. He also held leadership positions at Cerus Corporation and PPD-Development. Dr. Chanda has over thirty publications in various peer-reviewed journals. He received his Ph.D. in Pharmacology/Toxicology at Northeast Louisiana University and completed postdoctoral fellowships at University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina.